X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs SANOFI INDIA - Comparison Results

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES SANOFI INDIA ALKEM LABORATORIES/
SANOFI INDIA
 
P/E (TTM) x - 33.9 - View Chart
P/BV x 6.1 6.5 94.1% View Chart
Dividend Yield % 0.7 0.6 121.3%  

Financials

 ALKEM LABORATORIES   SANOFI INDIA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
SANOFI INDIA
Dec-17
ALKEM LABORATORIES/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs1,5894,945 32.1%   
Low Rs1,2323,901 31.6%   
Sales per share (Unadj.) Rs417.51,081.8 38.6%  
Earnings per share (Unadj.) Rs56.3141.6 39.8%  
Cash flow per share (Unadj.) Rs64.7185.9 34.8%  
Dividends per share (Unadj.) Rs12.7033.00 38.5%  
Dividend yield (eoy) %0.90.7 120.7%  
Book value per share (Unadj.) Rs292.9868.8 33.7%  
Shares outstanding (eoy) m119.5723.03 519.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.44.1 82.6%   
Avg P/E ratio x25.131.2 80.2%  
P/CF ratio (eoy) x21.823.8 91.6%  
Price / Book Value ratio x4.85.1 94.6%  
Dividend payout %22.623.3 96.8%   
Avg Mkt Cap Rs m168,653101,862 165.6%   
No. of employees `000NA3.2 0.0%   
Total wages/salary Rs m9,1713,685 248.9%   
Avg. sales/employee Rs ThNM7,691.9-  
Avg. wages/employee Rs ThNM1,137.7-  
Avg. net profit/employee Rs ThNM1,006.5-  
INCOME DATA
Net Sales Rs m49,91524,914 200.4%  
Other income Rs m1,645807 203.9%   
Total revenues Rs m51,56125,721 200.5%   
Gross profit Rs m8,4825,372 157.9%  
Depreciation Rs m1,0061,022 98.4%   
Interest Rs m67111 6,096.4%   
Profit before tax Rs m8,4515,146 164.2%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6061,886 85.2%   
Profit after tax Rs m6,7313,260 206.5%  
Gross profit margin %17.021.6 78.8%  
Effective tax rate %19.036.6 51.9%   
Net profit margin %13.513.1 103.1%  
BALANCE SHEET DATA
Current assets Rs m27,06214,432 187.5%   
Current liabilities Rs m15,3246,010 255.0%   
Net working cap to sales %23.533.8 69.6%  
Current ratio x1.82.4 73.5%  
Inventory Days Days6761 109.2%  
Debtors Days Days4128 144.9%  
Net fixed assets Rs m12,6107,991 157.8%   
Share capital Rs m239230 103.8%   
"Free" reserves Rs m34,49019,778 174.4%   
Net worth Rs m35,02720,008 175.1%   
Long term debt Rs m1,2120-   
Total assets Rs m54,38727,770 195.8%  
Interest coverage x13.6468.8 2.9%   
Debt to equity ratio x00-  
Sales to assets ratio x0.90.9 102.3%   
Return on assets %13.611.8 115.5%  
Return on equity %19.216.3 117.9%  
Return on capital %24.925.8 96.4%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,5636,306 104.1%   
Fx outflow Rs m3,0125,257 57.3%   
Net fx Rs m3,5521,049 338.6%   
CASH FLOW
From Operations Rs m7,2594,351 166.8%  
From Investments Rs m1,864-787 -236.9%  
From Financial Activity Rs m-9,273-1,884 492.2%  
Net Cashflow Rs m-1501,680 -8.9%  

Share Holding

Indian Promoters % 66.9 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 33.1 14.4 229.9%  
FIIs % 0.0 14.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 10.5 -  
Shareholders   68,381 15,184 450.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   GSK PHARMA  ASTRAZENECA PHARMA  BIOCON   STERLING BIOTECH  JUBILANT LIFE SCIENCES  

Compare ALKEM LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Marginally Higher; Realty and Energy Stocks Witness Buying(Closing)

Indian share markets witnessed volatility during closing hours and ended their day marginally higher. Gains were largely seen in the realty sector.

Related Views on News

SANOFI INDIA Announces Quarterly Results (3QFY19); Net Profit Up 4.3% (Quarterly Result Update)

Mar 5, 2019 | Updated on Mar 5, 2019

For the quarter ended December 2018, SANOFI INDIA has posted a net profit of Rs 793 m (up 4.3% YoY). Sales on the other hand came in at Rs 7 bn (up 8.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (2QFY19); Net Profit Up 2.5% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, SANOFI INDIA has posted a net profit of Rs 1 bn (up 2.5% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY19); Net Profit Up 35.1% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, SANOFI INDIA has posted a net profit of Rs 996 m (up 35.1% YoY). Sales on the other hand came in at Rs 7 bn (up 13.8% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY18); Net Profit Up 37.5% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, SANOFI INDIA has posted a net profit of Rs 825 m (up 37.5% YoY). Sales on the other hand came in at Rs 6 bn (up 11.7% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Are You Ready for the Big Nifty Move in the March Expiry?(Profit Hunter)

Mar 8, 2019

History suggests the Nifty could make a big move in March. Are you prepared to benefit from this opportunity?

Smallcaps Are Rallying and You Need to Make the Most of It Now(Profit Hunter)

Mar 7, 2019

Did you just miss the smallcap rally? Or is there still time to catch up? Read on for answers and more...

The One Sector to Bet on Today as India Grows into a 10 Trillion Dollar Economy(The 5 Minute Wrapup)

Mar 7, 2019

India's defence sector is suddenly under the spotlight. Can this sector ride along India's long-term growth story?

Is it the Right Time to Buy Mid and Small Caps Now?(The 5 Minute Wrapup)

Mar 6, 2019

Mid and Small Caps have underperformed large caps in the past year. Is the tide about to turn?

The Jet Airways Crisis in 6 Charts(Sector Info)

Mar 5, 2019

What happened to Jet Airways, once among top 3 airlines in India? Is it another Kingfisher in the making? Read on...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Mar 18, 2019 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS